Tislelizumab Versus Docetaxel in Patients With Previously Treated Advanced NSCLC (RATIONALE-303): A Phase 3, Open-Label, Randomized Controlled Trial

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer（2023）

引用 13|浏览16

暂无评分

摘要

Tislelizumab was found to have a significantly improved and long-term clinical benefit in OS versus docetaxel in pretreated patients with advanced NSCLC, regardless of PD-L1 expression.

查看译文

关键词

Tislelizumab,Docetaxel,Non–small cell lung cancer,Randomized clinical trial

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要